These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 11487536)
1. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gordon FH; Lai CW; Hamilton MI; Allison MC; Srivastava ED; Fouweather MG; Donoghue S; Greenlees C; Subhani J; Amlot PL; Pounder RE Gastroenterology; 2001 Aug; 121(2):268-74. PubMed ID: 11487536 [TBL] [Abstract][Full Text] [Related]
2. Natalizumab for induction of remission in Crohn's disease. MacDonald JK; McDonald JW Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580 [TBL] [Abstract][Full Text] [Related]
3. Natalizumab for induction of remission in Crohn's disease. Macdonald JK; McDonald JW Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112 [TBL] [Abstract][Full Text] [Related]
4. Natalizumab for active Crohn's disease. Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S; N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039 [TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Sands BE; Kozarek R; Spainhour J; Barish CF; Becker S; Goldberg L; Katz S; Goldblum R; Harrigan R; Hilton D; Hanauer SB Inflamm Bowel Dis; 2007 Jan; 13(1):2-11. PubMed ID: 17206633 [TBL] [Abstract][Full Text] [Related]
6. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ; Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865 [TBL] [Abstract][Full Text] [Related]
8. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Ito H; Takazoe M; Fukuda Y; Hibi T; Kusugami K; Andoh A; Matsumoto T; Yamamura T; Azuma J; Nishimoto N; Yoshizaki K; Shimoyama T; Kishimoto T Gastroenterology; 2004 Apr; 126(4):989-96; discussion 947. PubMed ID: 15057738 [TBL] [Abstract][Full Text] [Related]
9. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Khanna R; Preiss JC; MacDonald JK; Timmer A Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580 [TBL] [Abstract][Full Text] [Related]
10. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease. Ko HH; Bressler B Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431 [TBL] [Abstract][Full Text] [Related]
11. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Feagan BG; Greenberg GR; Wild G; Fedorak RN; Paré P; McDonald JW; Cohen A; Bitton A; Baker J; Dubé R; Landau SB; Vandervoort MK; Parikh A Clin Gastroenterol Hepatol; 2008 Dec; 6(12):1370-7. PubMed ID: 18829392 [TBL] [Abstract][Full Text] [Related]
12. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Gordon FH; Hamilton MI; Donoghue S; Greenlees C; Palmer T; Rowley-Jones D; Dhillon AP; Amlot PL; Pounder RE Aliment Pharmacol Ther; 2002 Apr; 16(4):699-705. PubMed ID: 11929387 [TBL] [Abstract][Full Text] [Related]
13. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin. Lanzarotto F; Carpani M; Chaudhary R; Ghosh S Drugs; 2006; 66(9):1179-89. PubMed ID: 16827596 [TBL] [Abstract][Full Text] [Related]